SCHEMBL3585261

SCHEMBL3585261

CC(=O)c1ccsc1S(N)(=O)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 5/20 0.42
PTK2 Q05397 1/20 0.41
ALDH1A1 P00352 4/20 0.39
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
MAPT P10636 3/20 0.39
MAPK1 P28482 1/20 0.39
CA1 P00915 3/20 0.35
CA9 Q16790 3/20 0.35
CA12 O43570 2/20 0.35
STS P08842 1/20 0.35
LMNA P02545 2/20 0.34
GLA P06280 2/20 0.34
KDM4E B2RXH2 2/20 0.34
USP2 O75604 1/20 0.34
HSD17B10 Q99714 1/20 0.34
POLB P06746 1/20 0.34
NR4A1 P22736 1/20 0.34
RECQL P46063 1/20 0.34
ESR2 Q92731 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23531735 0.82 PTK2 (0.36) CA2PTK2ALDH1A1KMT2AMEN1
SCHEMBL1436752 0.82 PTK2 (0.37) CA2PTK2ALDH1A1KMT2AMEN1
SCHEMBL11723057 0.82 MEN1 (0.43) CA2ALDH1A1KMT2AMEN1MAPT
SCHEMBL334875 0.79 PTK2 (0.38) CA2PTK2ALDH1A1KMT2AMEN1
SCHEMBL10493783 0.79 ALDH1A1 (0.38) CA2PTK2ALDH1A1KMT2AMEN1
SCHEMBL1559973 0.76 GSK3B (0.38) CA2ALDH1A1KMT2AMEN1MAPT
SCHEMBL2200875 0.76 CA1 (0.37) CA2ALDH1A1KMT2AMEN1MAPT
SCHEMBL10370580 0.73 CA2 (0.53) CA2ALDH1A1KMT2AMEN1MAPT
SCHEMBL11053655 0.73 STS (0.45) CA2ALDH1A1KMT2AMEN1MAPT
SCHEMBL3044354 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104031021-A Method for preparing intermediate thiophene sulfonamide of brinzolamide JINAN CHENGHUI SHUANGDA CHEMICAL CO LTD 2014-09-10 CN claimed
US-20100009977-A1 Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. USV LTD. (IN) 2010-01-14 US claimed
EP-2079749-A2 IMPROVED PROCESS FOR THE PREPARATION OF (R)-(+)-4-(ETHYIAMINO)-3,4-DIHYDRO-2-(3- METHOXYPROPYL)-2H-THIENO[3,2-E]-L,2-THIAZINE-6-SULFONAMIDE-L,L-DIOXIDE USV LIMITED (IN) 2009-07-22 EP claimed
WO-2008062463-A2 IMPROVED PROCESS FOR THE PREPARATION OF (R)-(+)-4-(ETHYIAMINO)-3,4-DIHYDRO-2-(3- METHOXYPROPYL)-2H-THIENO[3,2-E]-L,2-THIAZINE-6-SULFONAMIDE-L,L-DIOXIDE USV LIMITED (IN) 2008-05-29 WO claimed
CN-104031021-A Method for preparing intermediate thiophene sulfonamide of brinzolamide JINAN CHENGHUI SHUANGDA CHEMICAL CO LTD 2014-09-10 CN disclosed
US-8344136-B2 Process for the preparation of brinzolamide PHF S.A. (CH) 2013-01-01 US disclosed
US-8344136-B2 Process for the preparation of brinzolamide PHF S.A. (CH) 2013-01-01 US disclosed
US-20110118461-A1 PROCESS FOR THE PREPARATION OF BRINZOLAMIDE F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2011-05-19 US disclosed
US-20110118461-A1 PROCESS FOR THE PREPARATION OF BRINZOLAMIDE F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2011-05-19 US disclosed
US-20100317655-A1 SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE AUSPEX PHARMACEUTICALS, INC. (US) 2010-12-16 US disclosed
US-20100317655-A1 SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE AUSPEX PHARMACEUTICALS, INC. (US) 2010-12-16 US disclosed
US-20100317655-A1 SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE AUSPEX PHARMACEUTICALS, INC. (US) 2010-12-16 US disclosed
WO-1996022099-A1 OPHTHALMIC COMPOSITIONS FOR TREATING GLAUCOMA ALCON LABORATORIES, INC. (US) 1996-07-25 WO disclosed
US-5538966-A ENZYME INHIBITORS FOR TREATMENT OF GLAUCOMA ALCON LABORATORIES, INC. (US) 1996-07-23 US disclosed
WO-1995019981-A1 THIENOTHIAZINE SULFONAMIDE DERIVATIVES PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS CARBONIC ANHYDRASE INHIBITORS ALCON LABORATORIES, INC. (US) 1995-07-27 WO disclosed
US-5378703-A FOR CONTROLLING INTRAOCULAR PRESSURE ALCON LABORATORIES, INC. (US) 1995-01-03 US disclosed
US-5240923-A Treating glaucoma ALCON LABORATORIES, INC. (US) 1993-08-31 US disclosed
EP-0527801-A1 THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS ALCON LABORATORIES, INC. (US) 1993-02-24 EP disclosed
US-5153192-A For controlling intraocular pressure ALCON LABORATORIES, INC. (US) 1992-10-06 US disclosed
WO-1991015486-A1 THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS ALCON LABORATORIES, INC. (US) 1991-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100009977-A1 Process for the preparation of (R)-(+)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide. SULT1E1, SULT1A1, SULT2A1 CA2 1631/4885PTK2 3775/4885ALDH1A1 146/4885
US-20100317655-A1 SULFONAMIDE INHIBITORS OF CARBONIC ANHYDRASE CA2, CA9, CA1 CA2 1/4885PTK2 4338/4885ALDH1A1 463/4885
US-20110118461-A1 PROCESS FOR THE PREPARATION OF BRINZOLAMIDE CYP3A4, CYP4B1, SULT1E1 CA2 1003/4885PTK2 4095/4885ALDH1A1 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.